The National Institute for Pharmaceutical Technology and Education, Inc. (NIPTE) is pleased to announce that the University of Rochester Medical Center (URMC) has become its 14th member institution. Its admission has been unanimously approved by the Board of Directors followed the unanimous vote by the Faculty Committee.
URMC brings on board its vast experience and significant capabilities in the clinical trials supply chain management and monitoring through its Clinical Materials Services Unit (CMSU). It provides a full array of investigational drug/device services for many large, multi-center, multi-year clinical trials being conducted by the URMC, external academic medical centers, pharmaceutical, biotech and contract research organizations. It currently acts as the “central pharmacy” for the National Institutes of Health’s NeuroNEXT network and is actively involved in drug development research through its NIH-funded Clinical and Translational Science Institute (CTSI) and Center for Human Experimental Therapeutics (CHET). Professor Karl Kieburtz, MD, MPH, a prominent clinical neurologist and URMC senior administrator who leads CTSI, will serve on the NIPTE Board of Directors.
NIPTE is a non-profit research organization headquartered in Minneapolis, MN whose membership includes 14 top US universities in pharmaceutical science and engineering. Current members are Duquesne University, Illinois Institute of Technology, Purdue University, Rutgers University, University of Puerto Rico, University of Connecticut, University of Iowa, University of Kansas, University of Kentucky, University of Maryland – Baltimore, University of Michigan, University of Minnesota, University of Rochester, and the University of Wisconsin.
- University of Rochester